Trial Condition(s):
Hypertension, Postmenopause
Study to evaluate the effect of a preparation containing DRSP 3 mg and E2 1 mg on blood pressure in mildly hypertensive postmenopausal women
Bayer Identifier:
91000
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
213
Trial Dates
Phase
3
Could I receive a placebo?
No
Products
Angeliq (E2/DRSP, BAY86-4891)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
| Locations |
|---|
Trial Design
A multicenter, double-blind, randomized, placebo-controlled study to evaluate the effect of a continuous-combined HRT preparation containing DRSP 3 mg and E2 1 mg on blood pressure in mildly hypertensive postmenopausal women
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
